The US is the bigger Point Of Care (PoC) Molecular Diagnostic market: $7.9 Bn against $1.5 Bn in 2023, about 5.3 times as large.
Canada grows faster: 9.3% a year, against 7.3%. The gap still grows from $6.4 Bn to $12.2 Bn by 2033.
Clinical research: 268 active trials in the US, 76 in Canada.
| Measure |  US |  Canada |
|---|---|---|
| Market size, 2023 | $7.9 Bn | $1.5 Bn |
| Market size, 2033 projected | $15.9 Bn | $3.6 Bn |
| Growth a year (CAGR) | 7.3% | 9.3% |
| Money added, 2023–2033 | $8 Bn | $2.1 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $23 | $36 |
| Active clinical trials | 268 | 76 |
| Full report | US report | Canada report |
Year by year, 2023 to 2033
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Point Of Care (PoC) Molecular Diagnostic, US or Canada?
The US is the bigger Point Of Care (PoC) Molecular Diagnostic market: $7.9 Bn against $1.5 Bn in 2023, about 5.3 times as large.
Which grows faster in Point Of Care (PoC) Molecular Diagnostic, US or Canada?
Canada grows faster: 9.3% a year, against 7.3%. The gap still grows from $6.4 Bn to $12.2 Bn by 2033.
More Point Of Care (PoC) Molecular Diagnostic comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.